Tonix Pharmaceuticals Holding (TNXP) Other financing activities (2013 - 2026)

Tonix Pharmaceuticals Holding has reported Other financing activities for 12 years, with the latest figure at $79000.0 in Q1 2026.

• On a quarterly basis, Other financing activities changed N/A year-over-year to $79000.0 in Q1 2026; TTM through Jun 2026 was $83000.0, a N/A change from a year earlier, with the FY2024 full-year figure at $27000.0, down 99.88% from the prior year.
• Other financing activities was $79000.0 for Q1 2026 at Tonix Pharmaceuticals Holding, up from $4000.0 in the prior quarter.
• The five-year high for Other financing activities was $22.5 million in Q4 2023, with the low at $4000.0 in Q3 2024.
• Average Other financing activities over 4 years is $3.8 million, with a median of $34500.0 recorded in 2022.
• The sharpest annual moves came in 2022 and 2023: Other financing activities surged 42.86% in 2022, then decreased 27.5% in 2023.
• Over 4 years, Other financing activities stood at $40000.0 in 2022, then surged by 56257.5% to $22.5 million in 2023, then plunged by 99.98% to $4000.0 in 2024, then jumped by 1875.0% to $79000.0 in 2026.
• The last three Other financing activities figures came in at $79000.0 (Q1 2026), $4000.0 (Q3 2024), and $23000.0 (Q1 2024), per Business Quant data.